secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silo Pharma, Inc. (SILO)
CIK:        0001514183
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001213900-23-086959
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silo Pharma amends U. Maryland license, sets new development milestones through 2033
--------------------------------------------------------------------------------

- Third Amendment to Master License Agreement replaces entire diligence milestone schedule (Schedule C).
- Key new milestones: complete in vitro peptide binding study by March 30, 2024; preclinical safety/efficacy by Sept 30, 2024.
- GMP production and animal testing deadline: Feb 12, 2026; IND filing by Feb 12, 2027; Phase 1 first dosing by Feb 12, 2028.
- Phase 2 first dosing by Feb 12, 2029; NDA filing by Feb 12, 2032; first commercial sale by Feb 12, 2033.
- Royalty and other payment obligations under original MLA remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514183/000121390023086959/0001213900-23-086959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514183/000121390023086959/ea188215-8k_silo.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-086959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer